Innoviva Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Innoviva ha un patrimonio netto totale di $668.5M e un debito totale di $518.9M, che porta il suo rapporto debito/patrimonio netto a 77.6%. Le sue attività totali e le sue passività totali sono rispettivamente $1.2B e $563.1M. L'EBIT di Innoviva è $181.3M rendendo il suo rapporto di copertura degli interessi 34.5. Ha liquidità e investimenti a breve termine pari a $260.6M.

Informazioni chiave

77.6%

Rapporto debito/patrimonio netto

US$518.87m

Debito

Indice di copertura degli interessi	34.5x
Contanti	US$260.63m
Patrimonio netto	US$668.54m
Totale passività	US$563.07m
Totale attività	US$1.23b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $400.6M ) di HVE superano le sue passività a breve termine ( $223.8M ).

Passività a lungo termine: Le attività a breve termine di HVE ( $400.6M ) superano le sue passività a lungo termine ( $339.3M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 38.6% ) di HVE è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di HVE si è ridotto da 137% a 77.6% negli ultimi 5 anni.

Copertura del debito: Il debito di HVE è ben coperto dal flusso di cassa operativo ( 31.4% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di HVE sono ben coperti dall'EBIT ( 34.5 x copertura).

Innoviva Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

Recent updates

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

New minor risk - Financial position

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.23 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings released: EPS: US$3.81 (vs US$1.04 in 3Q 2021)

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Second quarter 2022 earnings released: EPS: US$0.013 (vs US$1.01 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Independent Chairman of the Board recently bought €216k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

New 90-day high: €10.20

New 90-day high: €10.00

Investor sentiment improved over the past week

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Third quarter earnings released

New 90-day low: €8.40

New 90-day low: €9.25

New 90-day low - €10.60

New 90-day low - €11.10

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane